Postdoctoral Training Fellow - Artificial Intelligence for Radiotherapy

Postdoctoral Training Fellow - Artificial Intelligence for Radiotherapy Radiotherapy & Imaging, The Institute of Cancer Research

Deadline: 15 May 2026. Salary: £45,600 to £51,450, from £45,600 in line with the PDTF pay scale, dependent on relevant Postdoctoral experience.

Under the guidance of Dr Matthew Blackledge, we are seeking to recruit a Postdoctoral Training Fellow to contribute to the development of treatment integrated, multimodal agentic AI to drive a step change in clinical radiotherapy by i) improving patient outcomes for cancers of unmet clinical need; and ii) increasing the efficiency of RT by enabling safe ultra hypofractionated treatments. The successful candidate will play a key role in developing vision language models (VLMs) to combine imaging data with human gestures (including eye gaze and voice dictated prompts) for robust tumour delineation, and innovating Bayesian enhanced AI to propagate uncertainties through the agentic workflow. The role will include attendance at relevant conferences and workshops, in addition to regular consultation with medical experts and publication of research in high impact journals.

Qualifications

• A PhD in computational science, artificial intelligence and/or image processing
• Practical experience with Python programming
• Experience with medical datasets, including imaging, clinical reports and/or radiotherapy
• Candidates who are nearing completion of their PhD may apply, but confirmation of an awarded PhD is required within 6 months of employment

The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years.

About the Group

The Blackledge Lab is based at the Institute of Cancer Research (ICR) in London, England. The lab was founded in 2019 with a focus on understanding the interface between medical imaging and computational science in oncology. In particular we aim to develop techniques that monitor imaging changes that inform on patient response and toxicity following radiotherapy. Our enthusiastic team of scientists is passionate to translate their research into clinically practical solutions to ensure that patients can benefit from emerging computational techniques. We actively engage with commercial partners to transfer our research into clinical tools.

The Division of Radiotherapy and Imaging investigates new imaging methods to diagnose cancer and ways in which advances in technology and molecular biology can improve radiation treatment. It is also increasingly concerned with the use of imaging to evaluate the response to treatment in vivo, through techniques measuring aspects of tumour biology. Researchers in the division are also interested in developing ways to increase the effectiveness of radiotherapy by combining it with other treatments and developing multimodality imaging to evaluate response to treatment in vivo.

Benefits

• A dynamic and supportive research environment
• Access to state of the art facilities and professional development opportunities
• Collaboration with leading researchers in the field
• Competitive salary and pension

Contact: Dr Matthew Blackledge.